Lipocine Statistics
Share Statistics
Lipocine has 5.35M
shares outstanding. The number of shares has increased by 0.05%
in one year.
| Shares Outstanding | 5.35M |
| Shares Change (YoY) | 0.05% |
| Shares Change (QoQ) | 0.05% |
| Owned by Institutions (%) | 11.32% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 6 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 71.89K, so 1.34% of the outstanding
shares have been sold short.
| Short Interest | 71.89K |
| Short % of Shares Out | 1.34% |
| Short % of Float | 1.38% |
| Short Ratio (days to cover) | 5.52 |
Valuation Ratios
The PE ratio is 3119.51 and the forward
PE ratio is -2.95.
Lipocine's PEG ratio is
-31.18.
| PE Ratio | 3119.51 |
| Forward PE | -2.95 |
| PS Ratio | 2.33 |
| Forward PS | 2.1 |
| PB Ratio | 1.24 |
| P/FCF Ratio | -19.87 |
| PEG Ratio | -31.18 |
Financial Ratio HistoryEnterprise Valuation
Lipocine has an Enterprise Value (EV) of 19.85M.
| EV / Sales | 1.77 |
| EV / EBITDA | -17.82 |
| EV / EBIT | -16.25 |
| EV / FCF | -15.14 |
Financial Position
The company has a current ratio of 14.75,
with a Debt / Equity ratio of 0.
| Current Ratio | 14.75 |
| Quick Ratio | 14.75 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 0.04% and Return on Invested Capital is -5.09%.
| Return on Equity | 0.04% |
| Return on Assets | 0.04% |
| Return on Invested Capital | -5.09% |
| Revenue Per Employee | $699,884 |
| Profits Per Employee | $522 |
| Employee Count | 16 |
| Asset Turnover | 0.5 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 681 |
| Effective Tax Rate | 7.54% |
Stock Price Statistics
The stock price has increased by -25.11% in the
last 52 weeks. The beta is 1.51, so Lipocine's
price volatility has been higher than the market average.
| Beta | 1.51 |
| 52-Week Price Change | -25.11% |
| 50-Day Moving Average | 3.24 |
| 200-Day Moving Average | 4.36 |
| Relative Strength Index (RSI) | 65.15 |
| Average Volume (20 Days) | 15,573 |
Income Statement
In the last 12 months, Lipocine had revenue of 11.2M
and earned 8.35K
in profits. Earnings per share was 0.
| Revenue | 11.2M |
| Gross Profit | 11.2M |
| Operating Income | -1.16M |
| Net Income | 8.35K |
| EBITDA | -1.11M |
| EBIT | -1.16M |
| Earnings Per Share (EPS) | 0 |
Full Income StatementBalance Sheet
The company has 6.21M in cash and 0 in
debt, giving a net cash position of 6.21M.
| Cash & Cash Equivalents | 6.21M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -199.77M |
| Total Assets | 22.51M |
| Working Capital | 20.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -1.22M
and capital expenditures -90.09K, giving a free cash flow of -1.31M.
| Operating Cash Flow | -1.22M |
| Capital Expenditures | -90.09K |
| Free Cash Flow | -1.31M |
| FCF Per Share | -0.25 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -10.31% and 0.07%.
| Gross Margin | 100% |
| Operating Margin | -10.31% |
| Pretax Margin | 0.08% |
| Profit Margin | 0.07% |
| EBITDA Margin | -9.95% |
| EBIT Margin | -10.31% |
| FCF Margin | -11.71% |
